Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Ohio Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$142,468

125 payments

Through program year 2025, Central Ohio Clinical Research LLC is reported as receiving $142,468 in research payments, across 125 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $759 1
2024 Research $17,856 9
2023 Research $18,547 18
2022 Research $17,234 19
2021 Research $50,585 33
2020 Research $37,486 45

Breakdown

Who paid Research payments · program years 2020–2025
  1. AbbVie, Inc. $78,595 72 payments
  2. Novo Nordisk AS $63,873 53 payments
Studies the money was for Research payments · program years 2020–2025
  1. Nn9924-4558 $27,478 20 payments
  2. Nn9535-4416 $26,895 20 payments
  3. A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $21,856 20 payments
  4. M16-283 $19,208 25 payments
  5. A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $13,412 3 payments
  6. Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $12,120 15 payments
  7. Nn9535-4506 $9,500 13 payments
  8. Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $4,000 1 payment
  9. Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $3,014 2 payments
  10. Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $2,885 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record